Name: Bezuclastinib in Gastrointestinal stromal tumor: KIT and PDGFRA tyrosine kinase inhibitors
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

KIT and PDGFRA tyrosine kinase inhibitors

4 evidence topics · 5 sources

First-line treatment of advanced or metastatic GIST

“Imatinib” (opens the source at this quote in a new tab)
“a category 1 preferred first-line treatment option for patients with advanced or metastatic GIST with imatinib-sensitive mutations” (opens the source at this quote in a new tab)

PDGFRA D842V-mutant GIST: first-line therapy

“avapritinib is used as first-line therapy” (opens the source at this quote in a new tab)

Second-line treatment after imatinib failure

“After the failure of imatinib, the standard second-line treatment is sunitinib 50 mg daily 4/2 (I,A) or 37.5 mg continuously (III,C).” (opens the source at this quote in a new tab)

Third-line and fourth-line treatment

“Regorafenib is regarded as standard therapy for the third-line treatment” (opens the source at this quote in a new tab)
“Ripretinib was approved by the FDA in May 2020” (opens the source at this quote in a new tab)
“as 4th line treatment.” (opens the source at this quote in a new tab)